Evaluation and Clinical Impact of Biofire FilmArray Pneumonia Panel Plus in ICU-Hospitalized COVID-19 Patients.
Dolores EscuderoJonathan Fernández-SuarezLorena ForcelledoSalvador BalboaJavier FernándezIvan AstolaBrigida QuindosRainer CamposFernando VázquezJosé Antonio BogaPublished in: Diagnostics (Basel, Switzerland) (2022)
Microbiological diagnosis by using commercial multiplex quantitative PCR systems provides great advantages over the conventional culture. In this work, the Biofire FilmArray Pneumonia Panel Plus (FAPP+) was used to test 144 low respiratory tract samples from 105 COVID-19 patients admitted to an Intensive Care Unit (ICU), detecting 78 pathogens in 59 (41%) samples. The molecular panel was evaluated by using the conventional culture (CC) as comparator, which isolated 42 pathogens in 40 (27.7%) samples. The overall percentage of agreement was 82.6%. Values of sensitivity (93%), specificity (62%), positive predictive value (50%), and negative predictive value (96%) were obtained. The mean time elapsed from sample extraction to modification of antibiotic treatment was 7.6 h. A change in antimicrobial treatment after the FAPP+ results was performed in 27% of patients. The FAPP+ is a highly sensitive diagnostic method that can be used to significantly reduce diagnostic time and that allows an early optimization of antimicrobial treatment.
Keyphrases
- intensive care unit
- sars cov
- respiratory tract
- mechanical ventilation
- staphylococcus aureus
- end stage renal disease
- coronavirus disease
- chronic kidney disease
- newly diagnosed
- mass spectrometry
- acute respiratory distress syndrome
- replacement therapy
- high throughput
- antimicrobial resistance
- single cell
- single molecule